Details of the Drug

General Information of Drug (ID: DML4RCG)

Drug Name
HS-110
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Drug Type
Vaccine
Cross-matching ID
TTD ID
D0F3EO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation B7-1 antigen (CD80) TTFZDNP CD80_HUMAN Not Available [2]
Endoplasmin (HSP90B1) TTFPKXQ ENPL_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Activation B7-1 antigen (CD80) DTT CD80 6.87E-07 -0.12 -0.3
Endoplasmin (HSP90B1) DTT HSP90B1 3.20E-17 0.31 0.62
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02117024) A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Heat Biologics.